Nicholas Khadder Net Worth

The estimated Net Worth of Nicholas Khadder is at least $1.26 Million dollars as of 8 January 2024. Mr. Khadder owns over 284 units of Standard BioTools Inc stock worth over $1,202 and over the last 11 years he sold FLDM stock worth over $0. In addition, he makes $1,257,780 as Senior Vice President, General Counsel, and Corporate Secretary at Standard BioTools Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Khadder FLDM stock SEC Form 4 insiders trading

Nicholas has made over 18 trades of the Standard BioTools Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 284 units of FLDM stock worth $1,054 on 8 January 2024.

The largest trade he's ever made was exercising 46,250 units of Standard BioTools Inc stock on 20 May 2021 worth over $171,588. On average, Nicholas trades about 2,719 units every 55 days since 2014. As of 8 January 2024 he still owns at least 324 units of Standard BioTools Inc stock.

You can see the complete history of Mr. Khadder stock trades at the bottom of the page.

Nicholas Khadder biography

Nicholas S. Khadder J.D. serves as Senior Vice President, General Counsel, Corporate Secretary of the Company. From 2010 to June 2016, Mr. Khadder held various positions at Amyris, Inc., an industrial biotechnology company, including senior vice president, general counsel and corporate secretary from 2013 to June 2016, interim general counsel from July 2013 to December 2013 and assistant general counsel from October 2010 to July 2013. Prior to joining Amyris, Mr. Khadder served in senior corporate counsel roles at LeapFrog Enterprises, Inc., an educational entertainment company, from August 2008 to September 2010, and at Protiviti, Inc., an internal audit and risk consulting firm, from June 2005 to July 2008. Before commencing his in-house legal career, Mr. Khadder was a corporate law associate at Fenwick & West LLP from 1998 to 2005. Mr. Khadder received a J.D. from Berkeley Law (the University of California, Berkeley, School of Law) and a B.A. in English from the University of California, Berkeley.

What is the salary of Nicholas Khadder?

As the Senior Vice President, General Counsel, and Corporate Secretary of Standard BioTools Inc, the total compensation of Nicholas Khadder at Standard BioTools Inc is $1,257,780. There are 4 executives at Standard BioTools Inc getting paid more, with Stephen Linthwaite having the highest compensation of $3,713,060.

How old is Nicholas Khadder?

Nicholas Khadder is 47, he's been the Senior Vice President, General Counsel, and Corporate Secretary of Standard BioTools Inc since 2020. There are 10 older and 2 younger executives at Standard BioTools Inc. The oldest executive at Standard BioTools Inc is Vikram Jog, 65, who is the Chief Financial Officer.

What's Nicholas Khadder's mailing address?

Nicholas's mailing address filed with the SEC is C/O THE COOPER COMPANIES, INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON, CA, 94583.

Insiders trading at Standard BioTools Inc

Over the last 14 years, insiders at Standard BioTools Inc have traded over $29,087,682 worth of Standard BioTools Inc stock and bought 4,143,303 units worth $24,269,186 . The most active insiders traders include Easterly Partners Llcle Par..., Capital Strategies, L.P.Lev..., and Samuel D Colella. On average, Standard BioTools Inc executives and independent directors trade stock every 9 days with the average trade being worth of $72,208. The most recent stock trade was executed by Nicolas Barthelemy on 1 April 2022, trading 20,993 units of FLDM stock currently worth $78,514.

What does Standard BioTools Inc do?

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.

Complete history of Mr. Khadder stock trades at Amyris Inc, Standard BioTools Inc, and Cooper Companies

Standard BioTools Inc executives and stock owners

Standard BioTools Inc executives and other stock owners filed with the SEC include:

• Stephen Linthwaite,
  President, Chief Executive Officer, Director
• Colin McCracken,
  Chief Commercial Officer
• Vikram Jog,
  Chief Financial Officer
• Bradley Kreger,
  Senior Vice President, Global Operations
• Nicholas Khadder,
  Senior Vice President, General Counsel, Corporate Secretary
• Colin McCracken,
  Chief Commercial Officer
• Vikram Jog,
  Chief Financial Officer
• Bradley Allen Kreger,
  Sr. VP of Global Operations
• Gerhard Burbach,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Carlos Paya,
  Independent Chairman of the Board
• Laura Clague,
  Independent Director
• Bill Colston,
  Independent Director
• Angela Peters,
  Chief HR Officer
• Mark Spearman,
  Sr. Director of Corp. Communications
• Peter DeNardo,
  Investor Relations
• Andrew Quong,
  Chief Science Officer
• Dr. Stephen R. Quake D.phil., Ph.D.,
  Co-Founder & Chairman of Advisory Board
• Venture Capital I Lpversant...,
  
• Capital Strategies, L.P.Lev...,
  
• John A Young,
  Director
• Steven Mc Phail,
  GM, PRODUCTION GENOMICS
• Mai Chan Yow,
  VP, WW Mfg & MD-Singapore
• Samuel D Colella,
  Director
• Jennifer Ling Lee,
  See Remarks
• Patrick S Jones,
  Director
• Gajus Vincent Worthington,
  President & CEO
• William Maxwell Smith,
  VP, Legal Affairs & GC
• Marc Unger,
  See Remarks
• Evan/ Fa Jones,
  Director
• Capital Strategies, L.P.Lev...,
  
• Capital Strategies, L.P.Lev...,
  
• Capital Strategies, L.P.Lev...,
  
• Ana K. Stankovic,
  Director
• Robert C Jones,
  Exec. VP, Research & Dev.
• Raymond J Whitaker,
  Director
• Kenneth J Nussbacher,
  Director
• Investments Pte Ltd.Biomedi...,
  
• Jeremy Loh,
  Director
• Partners, L.P.Euclid Sr Bio...,
  
• Easterly Partners Llcle Par...,